PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-36.86%
Negative ROE while RVPH stands at 1318.45%. Joel Greenblatt would investigate capital misallocation or uncompetitive positioning.
80.34%
Positive ROA while RVPH shows negative. Mohnish Pabrai might see this as a clear operational edge.
395.15%
ROCE below 50% of RVPH's 1372.56%. Michael Burry would question the viability of the firm’s strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.